Introduction {#sec1-1}
============

Oxaliplatin (OXA) is a novel platinum chemotherapeutic drug widely used in the treatment of various solid tumours mainly in digestive tract cancer (Hill et al., 2012). It induces one of the dose- limiting toxicities called peripheral neuropathy during or after chemotherapy. OXA-induced peripheral neuropathy (OXAIPN) represents as acute and chronic neuropathy. Acute neuropathy is a transient syndrome that is characterized by cold triggered paraesthesia and dysesthesias along with jaw spasms and cramps. Acute OXAIPN is usually reversible and resolves within the same cycle or later. It requires prolongation of OXA infusion when it is severe (Argyriou et al., 2008; Lehky et al., 2004).

Chronic type is purely sensory OXAIPN with a stocking and glove distribution. It develops gradually upon infusion of OXA and last for a long time or sometimes may persist even after completion of the treatment due to the accumulation of OXA in dorsal root ganglion of neurons (Argyriou et al., 2008). It is characterised by distal paraesthesia and dysesthesias and occurs at a threshold of 600-700 mg/m2 of the cumulative dose of OXA and affects between 50% and 70% of the patients (André et al., 2004; Argyriou et al., 2010). It became clinically important as many patients exhibit significant functional difficulties with daily activities that affect their quality of life (Cavaletti et al., 2013).

The exact molecular basis for underlying oxaliplatin-induced polyneuropathy (OXAIPN) remains unclear (Zedan et al., 2014). Though clinical predictors for OXAIPN have been suggested, to date no reliable pharmacogenetics or molecular biomarkers have been identified with which to identify the patients who are at high risk of developing OXAIPN. To date, several single nucleotide polymorphisms (SNPs) in various genes are identified in the context of the toxicity and efficacy of OXA. These include genes encoding enzymes associated with detoxification or those linked with DNA repair pathways, membrane efflux proteins or voltage gated sodium channels (Argyriou et al., 2009, 2013a; Inada et al., 2010). However, these genes have not been validated in prospective studies.

The voltage gated sodium channels (SCNAs) play major role in electrical signaling processes in neurons and other excitable cells. To date nine sodium channel subunits have been identified (SCN1A-SCN5A, SCN8A-SCN11A). They are well distributed in dorsal root ganglion neurons and their axons of both central and peripheral nervous systems.

It is now well recognized that mutations in these SCNAs have been associated with various diseases like epilepsy, ataxia, myotonias, pain and paroxysmal extreme pain disorders in both central and peripheral nervous systems (Hoeijmakers et al., 2015; Waszkielewicz et al., 2013).

Genes like *SCN4A*, *SCN5A*, *SCN9A*, *SCN10A*, encode Nav1.4, Nav 1.5, Nav 1.7, Nav 1.8 isoforms respectively. During the last few years, the role of these four gene mutations were extensively addressed in painful neuropathy (Palmio et al., 2017). To date, there is limited data concerning the association of development of OXAIPN with voltage gated SCN polymorphisms. Taking into account these findings, in the present study, we aimed to explore the association between *SCN4A* (*rs2302237*), *SCN5A* (*11720524*), *SCN9A* (*rs674603* 0, *rs6754031*), *SCN10A* (*rs12632942*) SNPs and development of severe chronic OXAIPN in south Indian GIT cancer patients who are treated with oxaliplatin based chemotherapy.

Materials and Methods {#sec1-2}
=====================

Study design and patient selection {#sec2-1}
----------------------------------

This is a prospective cohort study. This study was carried out in 228 histologically confirmed gastrointestinal tract (GIT) cancer patients of either gender who were scheduled to receive oxaliplatin-based chemotherapeutic treatment at Regional Cancer Centre (RCC) in collaboration with the departments of pharmacology, neurology and Medical Oncology at JIPMER (Jawaharlal Institute of Postgraduate Medical Education and Research) India, from November 2014 to December 2016. All patients were followed up from the start of the oxaliplatin based chemotherapy until the occurrence of chronic OXAIPN or death or till completion of the treatment. Patients who were less than 18 years of age, patients with eastern cooperative oncology group (ECOG) performance status greater than 2, patients with the abnormal hepatic and renal functions, patients with abnormal electrophysiological profile, pregnant or lactating women and patients with neuropathy or receiving other drugs which cause neuropathy were excluded from the study. The study was approved by Institute ethics committee (Reg.No: ECR/342/Inst/PY/2013), JIPMER and was conducted with the ethical standards of the Declaration of Helsinki. Written informed consent was taken from all the participants before including them into the study.

Treatment protocol and end points in the study {#sec2-2}
----------------------------------------------

The allotment of GIT cancer patients to the treatment of OXA based chemotherapy was made according to treating medical oncologist's discretion. For CAPOX (capecitabine and oxaliplatin) and EOX (Epirubicin, Capecitabine and oxaliplatin) of OXA based chemotherapy regimens, OXA was administered at 130 mg/m^2^, three weekly, for eight cycles. For FOLFOX (leucovorin, 5-fluorouracil and oxaliplatin) and GEMOX (Gemcitabine and oxaliplatin) of OXA based chemotherapy regimens, OXA was infused intravenously for 2 hours at 85 and 100mg/m^2^, two weekly, for twelve cycles. Development of grade 4 chronic OXAIPN was the end point of the present study.

Assessment of oxaliplatin induced peripheral neuropathy in the study cohort {#sec2-3}
---------------------------------------------------------------------------

Patients who were included in the study underwent clinical evaluation at baseline (visit1) and during the course of treatment (at every cycle) to detect the OXAIPN. The patients who developed OXAIPN were considered as cases and the patients who did not develop OXAIPN were considered as controls. Chronic OXAIPN was graded according to the Common Terminology Criteria for Adverse Events, version 4.03.

DNA extraction and genotyping of selected SNPs in the study {#sec2-4}
-----------------------------------------------------------

Approximately five millilitre of peripheral venous blood was collected from each study patients in tubes containing 100 µL of 10% ethylene diamine tetra acetic acid (EDTA) and centrifuged at 2500 RPM for 5 minutes. The plasma was discarded and the pellets containing lymphocytes in the form of buffy coat along with red blood cells were stored at -80°C in the laboratory deep freezer until DNA extraction. The genomic DNA for genotyping was extracted from the peripheral lymphocytes by phenol--chloroform extraction method (Blin and Stafford, 1976) and was quantified by using multi-analyzer (TECAN Infinite M200, Switzerland).

The genotyping was carried out by Real-Time PCR (ABI Prism 7300, foster city, CA, USA) using validated Real-Time TaqMan single nucleotide polymorphism (SNP) genotyping assays (Applied Biosystems, Foster City, CA, USA) according to manufacturer instructions. The version 1.4 of 7300 sequence detection software was used for allelic discrimination. All samples were analysed in duplicates along with negative controls to ensure the authenticity of the results and the results were found to be 100% consistent. The details of various SNPs of SCNAs screened in this study are given in [Table 1](#T1){ref-type="table"}.

###### 

Details of Selected Voltage Gated Sodium Channel SNPs in the Study Cohort

  Gene     SNP type   SNP ID/ rs ID   Allele change   Gene location     Assay ID
  -------- ---------- --------------- --------------- ----------------- ------------------
  SCN4A    Intron     2302237         C/T             Chr.17:63971347   C\_\_15757352_10
  SCN5A    Intron     11720524        C/G             Chr.2:240878099   C\_ 30666704_10
  SCN9A    Missense   6746030         G/A             Chr.2:166242648   C_29330435_10
  SCN9A    Intron     6754031         T/G             Chr.2:166298928   C_29108389_10
  SCN10A   Missense   12632942        A/G             Chr.3:38723507    C_31683397_10

Statistical analyses {#sec2-5}
--------------------

We used descriptive statistics for the analysis of all variables (mean, standard deviation, percentage distribution). Clinical variables among patients who developed and who did not develop chronic OXAIPN were compared using Student's t-test or Mann-Whitney U test (age and cumulative dose of oxaliplatin) or Chi square test (gender, presence of diabetes mellitus, tumour type, type of treatment and tumour stage). Fisher's exact test was employed to determine the influence of different genotypes of various SCN polymorphisms with the incidence and severity of chronic OXAIPN. Allele frequency and genotype distributions for each SNP were also tested with chi square test for Hardy--Weinberg equilibrium (HWE) probability. Graph Pad Instat version 3.0 (Graph Pad Software Inc., San Diego, CA, USA) was used for all the statistical analyses. Two sided p value \<0.05 was considered statistically significant.

Results {#sec1-3}
=======

Characteristics of the study patients {#sec2-6}
-------------------------------------

A total of 228 GIT cancer patients were recruited in the study in a 26 month period between November 2014 and December 2016. Among 228 patients, there were 86 females and 142 males in the study with a median age of 53 (range: 19-75) years. Out of 228 cancer patients, 108 patients were from colon and rectal cancers, 111 patients were from gastric cancers and 9 patients were from pancreatic and biliary cancers, respectively. All the patients received a median dose of oxaliplatin at 780 mg/m^2^. The detailed demographic and clinical characteristics are given in [Table 2](#T2){ref-type="table"}.

###### 

Baseline and Clinical Characteristics of the Study Population (N=228)

  Variable                     No. of patients (%)
  ---------------------------- -------------------------------
  Age                          
   Median (range),years        53 (19-75)
  Gender                       
   Male                        142 (62.3)
   Female                      86 (37.7)
  ECOG-PS                      
   0                           22 (9.6)
   1                           175 (76.8)
   2                           31 (13.6)
  Height, (Cm)                 157.42±8.45
  Weight, (Kg)                 49.37±9.77
  BSA, (m^2)^                  1.51±0.91
  Comorbidity                  
   Nil                         192
   Diabetes mellitus           19
   Hypertension                16
   Bronchial asthma            2
   Hypothyroid                 2
  Site of cancer               
   Stomach                     111 (48.7)
   Colorectal                  108 (47.4)
   Gall bladder and pancreas   9 (3.9)
  Stage of cancer: n,%         
   Metastatic                  106 (46.5)
   Non-metastatic              122 (53.5)
  Type of chemotherapy         
   Adjuvant                    85 (37.3)
   Neoadjuvant                 30 (13.1)
   Palliative                  113 (49.6)
  Type of regimen              
   CAPOX                       123 (53.9)
   EOX                         76 (33.3)
   FOLFOX                      20 (8.8)
   GEMOX                       09 (4.0)
  Median dose (range) n, %     780 mg/m^2^ (260-1040mg/m^2^)

ECOG-PS, Eastern Cooperative Oncology Group Performance Status;BSA, Body Surface Area

Incidence and severity of chronic OXAIPN {#sec2-7}
----------------------------------------

Chronic OXAIPN was manifested in 130 (57.0%) of 228 cancer patients. The distribution of incidence and severity of chronic OXAIPN was graded at the final follow up i.e. at the end of chemotherapy. Grade1was found in 73 (56.1%) patients, grade 2 in 55(42.3%) patients and grade 3 in 2 (1.6%) patients respectively. The median time for the onset of chronic OXAIPN was 105 (42--168) days. In the study cohort the occurrence of chronic OXAIPN was related to the cumulative dose of OXA and patients receiving ≥ 780mg/m^2^ of OXA dose had a higher incidence rate of chronic OXAIPN (p=0.0001). Other demographic and clinical factors such as age, gender, performance status, comorbidity, site of cancer and type of chemotherapy regimen, were not associated with the occurrence of chronic OXAIPN ([Table 3](#T3){ref-type="table"}).

###### 

Association of Chronic OXAIPN with Baseline and Clinical Variables

  variable                                 Total no. of patients;N=228(%)   Chronic OXAIPN   P value      
  ------------------------ --------------- -------------------------------- ---------------- ------------ --------
  Age                                                                                                     
  Median 53                ≤53             122 (53.5)                       45 (45.9)        77 (59.2)    0.06
                           \>53            106 (46.5)                       53 (54.1)        53 (40.8)    
  Gender                                                                                                  
                           Male            142 (62.3)                       61 (62.2)        81 (62.3)    0.9
                           Female          86 (37.7)                        37 (37.8)        49 (37.7)    
  ECOG-PS                                                                                                 
                           0               22 (9.6)                         12 (12.2)        10 (7.7)     0.75
                           1               175 (76.8)                       72 (73.5)        103 (79.2)   
                           2               31 (13.6                         14 (14.3)        17 (13.1)    
  Site of cancer                                                                                          
                           Stomach         111 (48.7)                       44 (44.9)        67 (51.5)    0.2
                           Colorectal      108 (47.4)                       48 (49.0)        60 (46.2)    
                           Gall bladder/   9 (4.0)                          6 (6.1)          3 (2.3)      
                           pancreas                                                                       
  Type of chemotherapy                                                                                    
                           Adjuvant        85 (37.3)                        37 (37.8)        48 (36.9)    0.75
                           Neoadjuvant     30 (13.2)                        11 (11.2)        19 (14.6)    
                           Palliative      113 (49.5)                       50 (51.0)        63 (48.5)    
  Type of regimen                                                                                         
                           CAPOX           123 (53.9)                       46 (46.9)        77 (59.2)    0.1
                           EOX             76 (33.3)                        34 (34.7)        42 (32.3)    
                           FOLFOX          20 (8.8)                         12 (12.3)        8 (6.2)      
                           GEMOX           9 (4.0)                          6 (6.1)          3 (2.3)      
  Median dose 780mg/m^2^                                                                                  
                           \<780           90 (39.5)                        53 (54.1)        37 (28.5)    0.0001
                           ≥780            138 (60.5)                       45 (45.9)        93 (71.5)    

\* p value \<0.05 is statistically significant;ECOG-PS, Eastern Cooperative Oncology Group Performance Status;BSA: Body Surface Area

The genotype distribution, allele frequencies of SCNAs SNPs and their association with chronic OXAIPN in the study cohort {#sec2-8}
-------------------------------------------------------------------------------------------------------------------------

In the present study, genotypes of 5 SNPs of SCNAs correlated with the incidence and severity of chronic OXAIPN. Association between genotype and chronic OXAIPN were tested in different genetic models (Lewis, 2002) by using Fisher's exact test. With regarding genotyping distribution, all the 5 SNPs of SCNAs were within Hardy-Weinberg equilibrium (HWE) probability. Allelic frequency and genotype distributions of all the SNPs of SCNAs are given in [Table 4](#T4){ref-type="table"}.

###### 

Allele and Genotype Frequencies of Selected SNPs in the Study Population

  Gene and SNP (rsID)   Wild type homogenous genotype n(%)   Mutant heterogeneous genotype n(%)   Mutant homogeneous genotype n(%)   Dominant allele n(%)   Recessive allele n(%)
  --------------------- ------------------------------------ ------------------------------------ ---------------------------------- ---------------------- -----------------------
  SCN 4A                CC                                   CT                                   TT                                 C                      T
  rs2302237             176 (77.2)                           46 (20.2)                            6 (2.6)                            398 (87.3)             58 (12.7)
  SCN5A                 CC                                   CG                                   GG                                 C                      G
  rs11720524            165 (72.4)                           52 (22.8)                            11 (4.8)                           382 (83.8)             74 (16.2)
  SCN9A                 GG                                   GA                                   AA                                 G                      A
  rs6746030             160 (70.2)                           61 (26.8)                            7 (3.0)                            381 (83.6)             75 (16.4)
  SCN9A                 TT                                   TG                                   GG                                 T                      G
  rs6754031             109 (47.8)                           89 (39.0)                            30 (13.2)                          307 (67.3)             149 (32.7)
  SCN10A                AA                                   AG                                   GG                                 A                      G
  rs12632942            144 (63.2)                           78 (34.2)                            6 (2.6)                            366 (80.2)             90 (19.8)

Coming to association between SNPs genotyping and chronic OXAIPN, polymorphic variant of rs6746030 of SCN9A was significantly associated with higher incidence of chronic OXAIPN in two genetic models (AG vs GG: OR=2.16, 95% CI=1.14-4.06, P=0.02 and GA+AA vs GG: OR=1.8, 95%CI=1.04-3.4, P=0.04) but when we tested for severity of chronic OXAIPN the same SNP did not show any statistical significance. For rs6754031 polymorphism of SCN9A, we found that patients harbouring G polymorphic variant had lower risk of both the incidence and severity of chronic OXAIPN when compared to wild type TT genotype in dominant (TG+GG vs TT) and over dominant (TG vs TT+GG) models (dominant model: incidence, OR= 0.45, 95%CI = 0.22-0.77, p= 0.005; severity, OR= 0.43, 95% CI = 0.23-0.80, p = 0.01; over dominant model: incidence, OR=0.5, 95% CI = 0.32 - 0.9, p= 0.04, severity; OR= 0.36, 95% CI = 0.18-0.73, p = 0.006). SCN10A (rs12632942) polymorphic variant had highly significant association with clinically relevant severity (Grade 0+1 vs Grade 2+3) of chronic OXAIPN ([Table 4](#T4){ref-type="table"}) when compared to wild type allele A (P=0.006, OR=2.0, 95% CI=1.2 - 3.3). These findings indicate that SCN9A rs6754031 variant allele protects against both the development and severity of OXAIPN while other SCN9A rs6746030, SCN10A rs12632942 polymorphic variants were associated with either the development of chronic OXAIPN or severity of chronic OXAIPN ([Table 5](#T5){ref-type="table"}).

###### 

Association between Selected SNPs of SCNAs and Chronic OXAIPN (n=228)

  Gene and SNP            Total no. of patients, N=228 (%)   Grade 0 N=98   Grade1 N=73   Grade 2 N=55   Grade 3 N=2   Incidence of OXAIPN (Grade 1-3 Vs Grade 0) OR;(95%CI)   P value                                 Severity of OXAIPN (Grade 2+3 vs Grade 0+1) OR;(95%CI)   P value
  ----------------------- ---------------------------------- -------------- ------------- -------------- ------------- ------------------------------------------------------- --------------------------------------- -------------------------------------------------------- ---------------------------------------
  SCN4A--C?T rs2302237                                                                                                                                                                                                                                                          
   CC                     176 (77.2)                         74(75.5)       60 (82.2)     41 (74.5)      1(50.0)       Reference                                                                                       Reference                                                
   CT                     46 (20.2)                          21 (21.4)      13 (17.8)     11 (20.0)      1 (50.0)      1.15 (0.60-2.22)                                        0.78                                    0.88 (0.42-1.86)                                         0.9
   TT                     6 (2.6)                            3 (3.1)        0 (-)         3 (5.5)        0 (-)         1.37 (0.27-7.02)                                        0.69                                    0.31 (0.06-1.61)                                         0.32
   CC vs CT+TT                                                                                                         1.18(0.63-2.2)                                          0.71                                    0.77 (0.38-1.54)                                         0.58
   CC +CT vs TT                                                                                                        1.33 (0.26-6.77)                                        0.72                                    0.32(0.06-1.64)                                          0.33
   CT vs CC+TT                                                                                                         0.8 (0.4-1.6)                                           0.8                                     1.0 (0.5-2.2)                                            0.8
  SCN5A-C ?G rs11720524                                                                                                                                                                                                                                                         
   CC                     165 (72.4)                         74 (75.5)      46 (63.0)     44 (80.0)      1 (50.0)      Reference                                                                                       Reference                                                
   CG                     52 (22.8)                          19 (19.4)      21 (28.8)     11 (20.0)      1 (50.0)      0.70 (0.37-1.34)                                        0.37                                    1.25 (0.6-2.59)                                          0.67
   GG                     11 (4.8)                           5 (5.1)        6 (8.2)       0 (-)          0 (-)         1.02 (0.3-3.49)                                         0.96                                    \-                                                       \-
   CC vs CG+GG                                                                                                         0.75 (0.41-1.37)                                        0.44                                    1.59 (0.77-3.26)                                         0.26
   CC+CG vs GG                                                                                                         1.11 (0.32-3.75)                                        0.86                                    \-                                                       \-
   CG vs CC+GG                                                                                                         1.4 (0.7-2.6 )                                          0.3                                     0.87 (0.42-1.81)                                         0.85
  SCN9A- G?A rs6746030                                                                                                                                                                                                                                                          
   GG                     160 (70.2)                         76 (77.6)      47 (64.4)     35 (63.7)      2 (100.0)     Reference                                                                                       Reference                                                
   AG                     61 (26.8)                          18 (18.4)      23 (31.5)     20 (36.3)      0 (-)         0.46 (0.24-0.87)                                        0.02[\*](#t5f1){ref-type="table-fn"}    0.61 (0.32-1.18)                                         0.19
   AA                     07 (3.0)                           4 (4.0)        3 (4.1)       0 (-)          0 (-)         1.4 (0.31-6.8)                                          0.9                                     \-                                                       \-
   AG+AA vs GG                                                                                                         1.8 (1.04-3.4S)                                         0.04[\*](#t5f1){ref-type="table-fn"}    0.72(0.38-1.36)                                          0.4
   GG+AG vs AA                                                                                                         1.8 (0.39-8.2)                                          0.7                                     \-                                                       \-
   AG vs GG+AA                                                                                                         2.1 (1.17-4.1 )                                         0.1                                     1.7 (0.89-3.2 )                                          0.1
  SCN9A- T?G rs6754031                                                                                                                                                                                                                                                          
   TT                     109 (47.8)                         36 (36.7)      37 (50.7)     35 (63.7)      1 (50.0)      Reference                                                                                       Reference                                                
   TG                     89 (39.0)                          46 (46.9)      30 (41.1)     13 (23.6)      0 (-)         2.19 (1.21-3.86)                                        0.01[\*](#t5f1){ref-type="table-fn"}    2.88 (1.41-5.87)                                         0.004[\*](#t5f1){ref-type="table-fn"}
   GG                     30 (13.2)                          16 (16.4)      6 (8.2)       7 (12.7)       1 (50.0)      2.31 (1.02-5.26)                                        0.06[\*](#t5f1){ref-type="table-fn"}    1.35 (0.55-3.34)                                         0.65
   TG+GG vs TT                                                                                                         0.45 (0.22-0.77)                                        0.005[\*](#t5f1){ref-type="table-fn"}   0.43 (0.23-0.80)                                         0.01[\*](#t5f1){ref-type="table-fn"}
   TT+TG vs GG                                                                                                         1.61 (0.74-3.4)                                         0.3                                     0.9 (0.37-2.16)                                          0.82
   TG vs TT+GG                                                                                                         0.5 (0.32-0.9)                                          0.04[\*](#t5f1){ref-type="table-fn"}    0.36 (0.18-0.73)                                         0.006[\*](#t5f1){ref-type="table-fn"}
  SCN10- A?G rs12632942                                                                                                                                                                                                                                                         
   AA                     144 (63.2)                         65 (66.3)      50 (68.5)     27 (49.0)      2 (100.0)     Reference                                                                                                                                                
   AG                     78 (34.2)                          32 (32.6)      23 (31.5)     23 (41.8)      0 (-)         0.84 (0.48-1.47)                                        0.65                                    0.6 (0.31-1.13)                                          0.16
   GG                     6 (2.6)                            1 (1.1)        0 (-)         5 (9.2)        0 (-)         0.24 (0.02-2.13)                                        0.33                                    0.05 (0.005-0.44)                                        0.001[\*](#t5f1){ref-type="table-fn"}
   AG+GG vs AA                                                                                                         1.27 (0.73-2.19)                                        0.47                                    1.9 (1.07-3.64)                                          0.03[\*](#t5f1){ref-type="table-fn"}
   AA+AG vs GG                                                                                                         0.25 (0.02-2.24)                                        0.36                                    0.06 (0.006-0.53)                                        0.004[\*](#t5f1){ref-type="table-fn"}
   AG vs AA+GG                                                                                                         1.1 (0.64-1.9 )                                         0.7                                     1.42 (0.76 - 2.65)                                       0.3

p value \<0.05 is statistically significant;OR, Odd Ratio;95%CI, 95%Confidence Interval

*SCN4A* and *SCN5A* variants were neither associated with the development of chronic OXAIPN nor severity of chronic OXAIPN in the current study cohort. When we did subgroup analysis with patients who have received a median dose ≥780 mg/m^2^ of oxaliplatin, *rs2302237* variant of *SCN4A* in addition to *SCN9A* (*rs6754031*) and *SN10A* (*rs12632942*) has exhibited statistical significance with severity of chronic OXAIPN ([Table 6](#T6){ref-type="table"}).

###### 

Association between Selected SNPs of SCNAs and Chronic OXAIPN in Patients who Received a Median Dose ≥780 mg/m^2^ of Oxaliplatin (N=138)

  Gene and SNP            Total number of patients;N=138(%)   Grade0, N=45(%)   Grade1, N=47(%)   Grade2, N=45(%)   Grade3, N=1(%)   Incidence of OXAIPN;(Grade 1-3 vs Grade0 ) OR (95%CI)   P value   Incidence of OXAIPN;(Grade 2+3 vs Grade0+1 ) OR (95%CI)   P value
  ----------------------- ----------------------------------- ----------------- ----------------- ----------------- ---------------- ------------------------------------------------------- --------- --------------------------------------------------------- ----------------------------------------
  SCN4A--C?T rs2302237                                                                                                                                                                                                                                           
   CC                     114(82.6)                           39 (86.6)         44 (93.6)         31 (68.9)         0 (0.0)          Reference                                                                                                                   
   CT                     20 (14.5)                           5 (11.1)          3 (6.4)           11 (24.4)         1 (100.0)        0.6 (0.2-1.8)                                           0.5       0.24 ( 0.09-066)                                          0.008
   TT                     4 (2.9)                             1 (2.2)           0 (0.0)           3 (6.7)           0 (0.0)          0.6 (0.06-6.3)                                          0.7       0.1 (0.01-1.2)                                            0.1
   CT+TT vs CC                                                                                                                       1.56 (0.57-4.24)                                        0.5       4.46 (1.77-11.24)                                         0.002[\*](#t6f1){ref-type="table-fn"}
   CC+CT vs TT                                                                                                                       0.6 ( 0.06-6.7)                                         0.7       0.1 ( 0.01-1.5)                                           0.2
   CT vs CC+TT                                                                                                                       1.53 (0.52-4.53)                                        0.5       3.7 (1.39-9.8)                                            0.01[\*](#t6f1){ref-type="table-fn"}
  SCN5A-C ?G rs11720524                                                                                                                                                                                                                                          
   CC                     95 (68.8)                           31 (68.8)         30 (63.8)         34 (75.6)         0 (0.0)          Reference                                                                                                                   
   CG                     38 (27.5)                           11 (24.5)         15 (31.9)         11 (24.4)         1 (100.0)        0.8 (0.3-1.9)                                           0.8       1.2 (0.5-2.6)                                             0.7
   GG                     5 (3.7)                             3 (6.7)           2 (4.3)           0                 0 (0.0)          3.0 ( 0.4-19.5)                                         0.4       \-                                                        \-
   CC vs CG+GG                                                                                                                       0.9 ( 0.4-2.1)                                          0.9       1.4 ( 0.6-6.31)                                           0.4
   CC+CG vs GG                                                                                                                       3.2 (0.5-20.1)                                          0.3       \-                                                        \-
   CG vs CC+GG                                                                                                                       1.26 ( 0.56-2.8)                                        0.7       0.84 (0.40-1.99)                                          0.9
  SCN9A- G?A rs6746030                                                                                                                                                                                                                                           
   GG                     97 (70.3)                           30 (66.7          34 (72.3)         32 (71.1)         1 (100.0)        Reference                                                                                                                   
   GA                     41 (29.7)                           15 (33.3)         13 (27.7)         13 (28.9)         0 (0.0)          1.2 (0.59-2.7)                                          0.6       1.11 (0.5-2.4)                                            0.9
   AA                     Ab                                  \-                \-                \-                \-               \-                                                      \-        \-                                                        \-
   GG vs AG+AA                                                                                                                       \-                                                      \-        \-                                                        \-
   GG+AG vs AA                                                                                                                       \-                                                      \-        \-                                                        \-
   GA vs GG+AA                                                                                                                       0.77 (0.36-1.67)                                        0.6       0.9 (0.41-1.96)                                           0.9
  SCN9A- T?G rs6754031                                                                                                                                                                                                                                           
   TT                     61 (44.2)                           13 (28.9)         18 (38.3)         29 (64.4)         1 (100.0)        Reference                                                                                                                   
   TG                     56 (40.6)                           24 (53.3)         23 (48.9)         9 (20.0)          0 (0.0)          2.76 (1.23-6.22)                                        0.02      5.05 (2.11-12.09)                                         0.0003[\*](#t6f1){ref-type="table-fn"}
   GG                     21 (15.2)                           8 (17.8)          6 (12.8)          7 (15.6)          0 (0.0)          2.2 (0.7-6.6)                                           0.2       1.9 (0.6-5.4)                                             0.3
   TG+GG vs TT                                                                                                                       0.38 (0.17-0.81)                                        0.01      0.27 (0.12-0.57)                                          0.0009[\*](#t6f1){ref-type="table-fn"}
   TT+TG vs GG                                                                                                                       1.33 ( 0.5-3.4)                                         0.7       1.0 ( 0.3-2.6)                                            1
   TG vs TT+GG                                                                                                                       0.45 (0.22-0.94)                                        0.05      0.23 ( 0.1-0.53)                                          0.007[\*](#t6f1){ref-type="table-fn"}
  SCN10- A?G rs12632942                                                                                                                                                                                                                                          
   AA                     82 (59.4)                           31 (68.9)         30 (63.8)         20 (44.4)         1 (100.0)        Reference                                                                                                                   
   AG                     53 (38.4)                           14 (31.1)         17 (36.2)         22 (48.9)         0 (0.0)          0.5 ( 0.2-1.2)                                          0.2       0.4 (0.20-1.07)                                           0.08
   GG                     3 (2.2)                             0                 0                 3 (6.7)           0 (0.0)          \-                                                      \-        \-                                                        \-
   AG+GG vs AA                                                                                                                       1.82 (0.85-3.86)                                        0.1       2.34 (1.13-3.39)                                          0.03[\*](#t6f1){ref-type="table-fn"}
   AA+AG vs GG                                                                                                                       \-                                                      \-        \-                                                        \-
   AG vs AA+GG                                                                                                                       1.59 (0.75-3.39)                                        0.2       1.8 (0.87-3.71)                                           0.15

p value \<0.05 is statistically significant;OR, Odd Ratio;95%CI, 95%Confidence Interval

Discussion {#sec1-4}
==========

OXAIPN affects a considerable number of patients during the therapy with OXA and can lead to postponement of therapy temporarily or complete stoppage of the therapy (Baek et al., 2010; Lehky et al., 2004). Maximum number of patients recover from the OXAIPN upon a variable period of time but quality of life is affected in these patients due to nerve damage on long term (Argyriou et al., 2008; Padman et al., 2015). To date several studies have attempted to explain the mechanism of OXAIPN, but the molecular bases for this OXAIPN remain unclear.

The proposed pathogenesis for cumulative chronic OXAIPN is the decline in cellular metabolism and axoplasmic transport due to the drug OXA accumulation in dorsal root ganglia (DRG) cells, together with oxidative stress and mitochondrial dysfunction, thus producing apoptosis of DRG neuron (Argyriou et al., 2012; Cavaletti et al., 2011). Type of chemotherapy, cumulative dose, time of infusion, and the pre-existence of peripheral neuropathy prior to the infusion of OXA are the most common risk factors for the genesis of OXAIPN(Argyriou et al., 2013b; Grothey, 2005). Even though, a number of studies have identified risk factors for the development of OXAIPN but there is lack of a reliable or specific molecular genetic biomarker to determine a causal relationship with the development of chronic OXAIPN (Cavaletti et al., 2011; McWhinney et al., 2009).

Several pharmacogenetic studies have attempted to find the polymorphisms that contribute to the disparity in susceptibility to OXAIPN (Custodio et al., 2014; McWhinney et al., 2009). Among those studies, Lecomte et al study results found a significant correlation between the glutathione S-transferase p1 (GSTP1) polymorphism and chronic OXAIPN (Lecomte et al., 2006) but results from other studies reported contradicting findings with regarding the association of GSTP1 with OXAIPN (Kweekel et al., 2009; Ruzzo et al., 2007). Most of the studies have focused on a limited number of candidate genes that are involved in certain biologic functions to detect genetic polymorphisms which are associated with oxaliplatin drug sensitivity or resistance.

The present study evaluated whether there is an association of development and severity of chronic OXAIPN with various sodium channel polymorphic variants using different genetic models like codominant, dominant, recessive and additive model. Our study is the first study to explore the association between the SCNAs and chronic OXAIPN in all the possible genetic models which are available in literature. Our study results have shown that the presence of polymorphisms in sodium channel genes like *SCN4A* (*rs2302237*), *SCN9A* (*rs6746030*) and *SCN10A* (*rs12632942*) predicts either the occurrence or the severity of chronic OXAIPN in gastrointestinal cancer patients receiving OXA based chemotherapy while patients carrying *SCN9A rs6754031* variant allele have the lower chances of the development of severe chronic OXAIPN.

In a prospective study, different sodium channel polymorphisms were tested for susceptibility of OXAIPN development. The study results had proved that the presence of mutation in *SCN4A* (*rs2302237*) and *SCN10A* (*rs12632942*) predicts the development of acute OXAIPN (Argyriou et al., 2013a). In another recent study, various single nucleotide polymorphisms in SCN9A gene were tested for the development of chronic neuropathy. The study results showed that patients carrying SCN9A rs6746030 polymorphic variant had lower incidence of OXAIPN (Sereno et al., 2017). Similarly, in another prospective study, patients carrying SCN9A rs6754031 polymorphic variants had higher chances of development of fibromyalgia(Vargas-Alarcon et al., 2012).

To date there is limited data regarding the influence of voltage gated sodium channel polymorphisms with occurrence or severity of chronic OXAIPN. This study evaluated 5 polymorphisms in 4 sodium channel genes thought to be associated with various neurological diseases. Out of 5 polymorphisms 3 SNPs have been associated either with occurrence and severity of chronic neuropathy or protection against the development of chronic OXAIPN.

To the best of our knowledge, this study is the first and the largest prospective pharmacogenetics evaluation study that tested the genetic susceptibility of selected sodium channels in a homogenous cohort of south Indian GIT cancer patients. Candidate SNPs were selected on the basis of previous published data from retrospective or single arm studies. The present study did not check gene duplications and copy number variations correlated with the sodium channel genes. Hence a genome-wide association study with large patient sample size will help in finding out the range of impact of various pharmacogenetics factors.

The present study results have shown that the presence of polymorphisms in sodium channel genes predicts both the occurrence and severity of chronic OXAIPN in south Indian patients of GIT cancers who are receiving OXA based chemotherapy. However, further studies from independent groups are warranted to validate these results.
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